The news of Barclays maintaining an Overweight rating on Immunogen and raising the price target from $9 to $20 is positive for the stock. This indicates that the analyst believes the stock has potential for further growth and is likely to outperform the market. This could lead to increased investor interest and a potential short-term increase in the stock price.